Taro Pharmaceutical Industries Ltd (NYSE:TARO)
Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc.2019. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates.
© 2021 Cable News Network. A Warner Media Company. All Rights Reserved.
CNN Sans™ & © 2016 Cable News Network.
Taro Pharmaceutical Industries Ltd.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet. Copyright 2019© FactSet Research Systems Inc. All rights reserved. Source: FactSet
Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Source: FactSet
Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet, Dow Jones
Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones
ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Sources: FactSet, Dow Jones
Bonds: Bond quotes are updated in real-time. Sources: FactSet, Tullett Prebon
Currencies: Currency quotes are updated in real-time. Sources: FactSet, Tullett Prebon
Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Source: FactSet
Data are provided 'as is' for informational purposes only and are not intended for trading purposes. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.
Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019© Refinitiv. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies)
Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Source: Kantar Media
Taro Pharmaceutical Industries Ltd TARO:NYSE
- Day High64.90
- Day Low63.83
- Prev Close63.75
- 52 Week High80.00
- 52 Week High Date02/17/21
- 52 Week Low56.53
- 52 Week Low Date11/09/20
- Market Cap2.421B
- Shares Out37.93M
- 10 Day Average Volume0.01M
- Dividend Yield-
- YTD % Change-13.06
- EPS (TTM)0.76
- P/E (TTM)84.23
- Fwd P/E (NTM)15.34
- EBITDA (TTM)180.609M
- ROE (TTM)1.77%
- Revenue (TTM)578.45M
- Gross Margin (TTM)53.49%
- Net Margin (TTM)5.26%
- Debt To Equity (MRQ)0.00%
- Earnings Date10/26/2021
- Ex Div Date12/10/2018
- Div Amount12.8601
- Split Date-
- Split Factor-
There is no recent news for this security.
There is no recent news for this security.
Taro Pharmaceutical IndustriesNYSE:TARO Stock Report
Taro Pharmaceutical Industries Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$63.83|
|52 Week High||US$56.53|
|52 Week Low||US$80.00|
|1 Month Change||-3.23%|
|3 Month Change||-4.73%|
|1 Year Change||7.42%|
|3 Year Change||-32.80%|
|5 Year Change||-38.61%|
|Change since IPO||1,176.60%|
Recent News & UpdatesAug 03
We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative
Taro Pharmaceutical Industries Ltd.'s ( NYSE:TARO ) solid earnings announcement recently didn't do much to the stock...
|TARO||US Pharmaceuticals||US Market|
Return vs Industry: TARO underperformed the US Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: TARO underperformed the US Market which returned 27.6% over the past year.
Stable Share Price: TARO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: TARO's weekly volatility (3%) has been stable over the past year.
About the Company
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic.
Taro Pharmaceutical Industries Fundamentals Summary
|TARO fundamental statistics|
Earnings & Revenue
|TARO income statement (TTM)|
|Cost of Revenue||US$269.04m|
Last Reported Earnings
Jun 30, 2021
|Earnings per share (EPS)||0.78|
|Net Profit Margin||5.10%|
How did TARO perform over the long term?See historical performance and comparison
Is Taro Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: TARO ($63.83) is trading above our estimate of fair value ($0.19)
Significantly Below Fair Value: TARO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TARO is poor value based on its PE Ratio (81.7x) compared to the US Pharmaceuticals industry average (21.6x).
PE vs Market: TARO is poor value based on its PE Ratio (81.7x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: TARO is poor value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: TARO is good value based on its PB Ratio (1.5x) compared to the US Pharmaceuticals industry average (3.1x).
How is Taro Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TARO's forecast earnings growth (79.3% per year) is above the savings rate (2%).
Earnings vs Market: TARO's earnings (79.3% per year) are forecast to grow faster than the US market (15.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: TARO's revenue (6.2% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: TARO's revenue (6.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TARO's Return on Equity is forecast to be high in 3 years time
How has Taro Pharmaceutical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TARO has a large one-off loss of $140.0M impacting its June 30 2021 financial results.
Growing Profit Margin: TARO became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: TARO's earnings have declined by 48.1% per year over the past 5 years.
Accelerating Growth: TARO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: TARO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: TARO's Return on Equity (1.8%) is considered low.
How is Taro Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: TARO's short term assets ($1.5B) exceed its short term liabilities ($729.2M).
Long Term Liabilities: TARO's short term assets ($1.5B) exceed its long term liabilities ($26.1M).
Debt to Equity History and Analysis
Debt Level: TARO is debt free.
Reducing Debt: TARO had no debt 5 years ago.
Debt Coverage: TARO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: TARO has no debt, therefore coverage of interest payments is not a concern.
What is Taro Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TARO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TARO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TARO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TARO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TARO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Uday V. Baldota has been Director at Association for Accessible Medicines. He has been the Chief Executive Officer of Taro Pharmaceutical Industries Ltd. since August 28, 2017 and served as its Co-Chie...
Experienced Management: TARO's management team is seasoned and experienced (7 years average tenure).
Experienced Board: TARO's board of directors are considered experienced (6.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Taro Pharmaceutical Industries Ltd.'s employee growth, exchange listings and data sources
- Name: Taro Pharmaceutical Industries Ltd.
- Ticker: TARO
- Exchange: NYSE
- Founded: 1950
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.410b
- Shares outstanding: 37.75m
- Website: https://www.taro.com
Number of Employees
- Taro Pharmaceutical Industries Ltd.
- 14 Hakitor Street
- Haifa Bay
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 22:29|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
- Ark raptor
- Twin peaks bar denver
- Polaris rzr fuel pump
- Jsdoc module
- Crane operator salary
- Hannaford pay rate